BIRC5 (survivin): a pejorative prognostic marker in stage II/III breast cancer with no response to neoadjuvant chemotherapy

被引：0
|
作者：
A. S. Hamy
I. Bieche
J. Lehmann-Che
V. Scott
Ph. Bertheau
J. M. Guinebretière
M. C. Matthieu
B. Sigal-Zafrani
O. Tembo
M. Marty
B. Asselain
F. Spyratos
P. de Cremoux
机构：
[1] Institut Curie,Department of Biostatistics
[2] Institut Curie,Pharmacogenomics Unit, Department of Genetics
[3] Paris Diderot University,APHP Molecular Oncology Unit, Hôpital Saint Louis
[4] Institut Gustave Roussy,Biology Department
[5] Paris Diderot University,APHP Pathology Department, Hôpital Saint Louis
[6] Institut Curie,Pathology Department, Hôpital René
[7] Institut Gustave Roussy,Huguenin
[8] Institut Curie,Pathology Department
[9] Saint-Louis Hospital,Pathology Department
来源：
Breast Cancer Research and Treatment | 2016年 / 159卷
关键词：
Breast cancer; Neoadjuvant chemotherapy; Predictive;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：499 / 511
页数：12
相关论文
共 50 条
  • [1] BIRC5 (survivin): a pejorative prognostic marker in stage II/III breast cancer with no response to neoadjuvant chemotherapy
    Hamy, A. S.
    Bieche, I.
    Lehmann-Che, J.
    Scott, V.
    Bertheau, Ph.
    Guinebretiere, J. M.
    Matthieu, M. C.
    Sigal-Zafrani, B.
    Tembo, O.
    Marty, M.
    Asselain, B.
    Spyratos, F.
    de Cremoux, P.
    BREAST CANCER RESEARCH AND TREATMENT, 2016, 159 (03) : 499 - 511
  • [2] Survivin As a Predictive Biomarker of Complete Pathologic Response to Neoadjuvant Chemotherapy in Patients With Stage II and Stage III Breast Cancer
    Petrarca, Cristiane Rios
    Brunetto, Andre T.
    Duval, Vinicius
    Brondani, Adriana
    Carvalho, Gisele Pereira
    Garicochea, Bernardo
    CLINICAL BREAST CANCER, 2011, 11 (02) : 129 - 134
  • [3] Prognostic Significance of BIRC5/Survivin in Breast Cancer: Results from Three Independent Cohorts
    Oparina, Nina
    Erlandsson, Malin C.
    Faldt Beding, Anna
    Parris, Toshima
    Helou, Khalil
    Karlsson, Per
    Einbeigi, Zakaria
    Bokarewa, Maria I.
    CANCERS, 2021, 13 (09)
  • [4] Neoadjuvant chemotherapy in the treatment of stage II and III breast cancer
    Singletary, SE
    AMERICAN JOURNAL OF SURGERY, 2001, 182 (04) : 341 - 346
  • [5] Prognostic impact of AJCC response criteria for neoadjuvant chemotherapy in stage II/III breast cancer patients: breast cancer subtype analyses
    Yang, Yaewon
    Im, Seock-Ah
    Keam, Bhumsuk
    Lee, Kyung-Hun
    Kim, Tae-Yong
    Suh, Koung Jin
    Ryu, Han Suk
    Moon, Hyeong-Gon
    Han, Sae-Won
    Oh, Do-Youn
    Han, Wonshik
    Kim, Tae-You
    Park, In Ae
    Noh, Dong-Young
    BMC CANCER, 2016, 16
  • [6] Prognostic impact of AJCC response criteria for neoadjuvant chemotherapy in stage II/III breast cancer patients: breast cancer subtype analyses
    Yaewon Yang
    Seock-Ah Im
    Bhumsuk Keam
    Kyung‑Hun Lee
    Tae‑Yong Kim
    Koung Jin Suh
    Han Suk Ryu
    Hyeong-Gon Moon
    Sae‑Won Han
    Do‑Youn Oh
    Wonshik Han
    Tae‑You Kim
    In Ae Park
    Dong-Young Noh
    BMC Cancer, 16
  • [7] Taxane-based chemotherapy enhances response to neoadjuvant treatment for stage II and III breast cancer
    J. M. Andrade
    H. H. A. Carrara
    F. F. Pimentel
    H. R. C. Marana
    A. H. Macchetti
    L. R. Mouro
    F. E. Zola
    D. G. Tiezzi
    Medical Oncology, 2011, 28 : 65 - 69
  • [8] Taxane-based chemotherapy enhances response to neoadjuvant treatment for stage II and III breast cancer
    Andrade, J. M.
    Carrara, H. H. A.
    Pimentel, F. F.
    Marana, H. R. C.
    Macchetti, A. H.
    Mouro, L. R.
    Zola, F. E.
    Tiezzi, D. G.
    MEDICAL ONCOLOGY, 2011, 28 : S65 - S69
  • [9] Epirubicin, cyclophosphamide and weekly paclitaxel as neoadjuvant chemotherapy for stage II and III breast cancer
    David Aguiar Bujanda
    Uriel Bohn Sarmiento
    Miguel Ángel Cabrera Suárez
    Marta Pavcovich Ruiz
    Miguel Ángel Limeres González
    José Aguiar Morales
    Journal of Cancer Research and Clinical Oncology, 2006, 132 : 332 - 338
  • [10] Neoadjuvant chemotherapy for stage II–III breast cancer: a single-center experience
    Haidi Abd El Zaher
    Hamada Fathy
    Mohamed Abozeid
    Mohammed Faisal
    World Journal of Surgical Oncology, 21
12345